
Loading, please wait...

Loading, please wait...

Chronic periodontitis represents a widespread inflammatory disorder that degrades the structural anchorage of teeth. At the center of this destructive pathology lies Porphyromonas gingivalis, a keystone oral pathogen capable of orchestrating polymicrobial dysbiosis. Recent experimental studies highlight P. gingivalis ferroptosis as a central biological mechanism driving cell death in periodontal tissues. Ferroptosis is a distinct form of regulated cell death driven by iron-dependent accumulation of lethal lipid peroxides. Consequently, this pathway diverges markedly from conventional apoptosis, necrosis, or pyroptosis. When the bacterium colonizes subgingival pockets, it actively sequesters host iron to fuel its survival. However, this process simultaneously disrupts cellular redox equilibrium in surrounding host tissues. Clinicians now recognize that periodontal degradation extends beyond simple proteolytic cleavage of extracellular matrix fibers. Instead, the pathogen triggers host metabolic collapse and lipid peroxidation cascades. Therefore, exploring this iron-dependent regulated necrosis provides critical insights into the recalcitrant nature of periodontal lesions. Understanding these dynamic relationships allows dental specialists and pathologists to decipher complex host-pathogen interactions at the mucosal boundary.
The molecular cascade linking bacterial invasion to cellular demise relies on profound perturbations of iron metabolism. Porphyromonas gingivalis utilizes specialized surface hemophore systems and gingipain proteases to extract heme from erythrocytes. Consequently, this bacterial behavior alters intracellular iron handling in adjacent human gingival fibroblasts and macrophages. In healthy tissue, ferritin tightly complexes excess labial iron. Conversely, bacterial exposure upregulates transferrin receptor expression while triggering nuclear receptor coactivator 4-mediated ferritinophagy. As a result, the intracellular labile iron pool expands dramatically. This unbound ferrous iron catalyzes Fenton reactions that generate excessive hydroxyl radicals. Simultaneously, the pathogen stimulates acyl-CoA synthetase long-chain family member 4, which incorporates polyunsaturated fatty acids into membrane phospholipids. Thus, the host cell membrane becomes vulnerable to unrestrained lipid peroxidation. In addition, experimental models show elevated malondialdehyde and 4-hydroxynonenal concentrations in infected fibroblasts. Because the rate of free radical generation outpaces clearance mechanisms, the structural integrity of the cellular membrane quickly fails, culminating in catastrophic ferroptotic lysis.
Oral junctional epithelium serves as the primary barrier against persistent subgingival biofilms. Nevertheless, bacterial invasion compromises this defense through suppression of cellular antioxidant systems. Specifically, the pathogen suppresses the cystine-glutamate antiporter known as system xc-, lowering intracellular cystine uptake. Consequently, glutathione biosynthesis decreases significantly, starving glutathione peroxidase 4 of its essential cofactor. Without adequate enzyme activity, epithelial cells cannot reduce toxic lipid hydroperoxides into non-toxic lipid alcohols. Therefore, junctional integrity rapidly deteriorates. Studies demonstrate a marked reduction in crucial junctional proteins, including E-cadherin, occludin, and zonula occludens-1. As epithelial cells succumb to ferroptotic rupture, they release damage-associated molecular patterns into the extracellular matrix. These endogenous alarmins subsequently activate toll-like receptors and the NLRP3 inflammasome in infiltrating monocytes. In response, macrophages secrete high amounts of interleukin-1 beta and tumor necrosis factor-alpha. Furthermore, these inflammatory cytokines accelerate local osteoclastogenesis. Thus, a destructive feedback loop emerges wherein cellular ferroptosis amplifies inflammation and accelerates alveolar bone resorption.
While the pathogen promotes ferroptotic cell death in non-malignant connective tissues, it elicits an opposite effect within neoplastic environments. For instance, in oral squamous cell carcinoma, persistent bacterial colonization correlates with reduced ferroptotic vulnerability. Research indicates that the bacterium stimulates specific oncogenic pathways that enhance antioxidant defenses in malignant cells. Furthermore, bacterial components upregulate sirtuin signaling and nuclear factor erythroid 2-related factor 2 activity. Consequently, transformed oral keratinocytes maintain elevated glutathione peroxidase 4 levels despite substantial oxidative stress. This selective cytoprotection permits malignant cells to evade cell death during rapid tumor growth. In addition, the reprogrammed tumor microenvironment exhibits altered macrophage polarization and diminished iron-mediated lipid injury. As a result, tumor cells display heightened resistance to conventional chemotherapeutic agents that rely on ferroptosis induction. Therefore, the pathogen acts as a context-dependent modulator of cellular fate. It destroys healthy periodontal barriers through unchecked lipid peroxidation, yet protects neoplastic tissues from metabolic demise.
Uncovering these distinct pathways creates compelling opportunities for novel host-modulatory periodontitis therapies. Currently, standard clinical protocols focus primarily on mechanical debridement and systemic or local antimicrobial therapy. However, these traditional approaches do not directly halt the intracellular cascades driving ferroptotic tissue degradation. Researchers are therefore evaluating pharmacological inhibitors of ferroptosis to preserve periodontal architecture. For example, small-molecule lipophilic radical traps like ferrostatin-1 show promise in preclinical models. In addition, iron chelators such as deferoxamine prevent iron overload and restore barrier junctions in gingival tissues. Nutritional approaches that replenish intracellular glutathione reserves also warrant careful clinical consideration. Furthermore, monitoring lipid peroxidation biomarkers in gingival crevicular fluid may enable early disease detection before severe radiographic bone loss occurs. Integrating targeted antioxidants into routine periodontal management could significantly reduce connective tissue loss. Ultimately, bridging microbiological control with ferroptosis-targeted cytoprotection provides a modern therapeutic avenue for managing refractory oral and systemic inflammatory diseases.
Ferroptosis is an iron-dependent form of non-apoptotic cell death characterized by severe lipid peroxidation and mitochondrial shrinkage. Unlike apoptosis, it does not involve caspase activation, chromatin condensation, or apoptotic body formation. Instead, cellular membrane integrity fails completely, releasing damage-associated molecular patterns that provoke intense secondary inflammation and severe alveolar bone degradation across surrounding periodontal supporting structures.
The bacterium uses gingipains to degrade hemoglobin and transferrin, releasing abundant extracellular iron. Concurrently, it upregulates host transferrin receptors while activating nuclear receptor coactivator 4-mediated ferritinophagy. This targeted degradation of intracellular ferritin expands the labile iron pool, which subsequently drives Fenton reactions, toxic hydroxyl radical generation, and lethal membrane lipid peroxidation in fibroblasts and epithelial cells.
In oral squamous cell carcinoma, the pathogen activates cytoprotective pathways like Nrf2 and sirtuin signaling, which upregulate glutathione peroxidase 4 and promote antioxidant defense. This context-dependent mechanism protects malignant cells from ferroptotic death, whereas in non-transformed healthy gingival tissue, the bacterium overwhelms antioxidant systems, accelerates iron accumulation, and promotes rapid inflammatory cell destruction.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. It is intended solely for healthcare professionals and medical researchers. Clinical decisions should be guided by qualified healthcare providers based on individual patient assessment and prevailing clinical guidelines. The authors and publishers disclaim any liability for decisions made based on this material. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Porphyromonas gingivalis drives tissue destruction by disrupting iron homeostasis and triggering ferroptosis, while paradoxically conferring ferroptosis resistance in neoplastic tissues. This review highlights key molecular mechanisms, diagnostic insights, and therapeutic possibilities.
Today

The GendAge weight loss study investigates how sex hormones, age, and menopausal status modulate caloric restriction response. By comparing metabolic adaptations across younger and older cohorts, this controlled feeding trial aims to refine precision dietary guidance for effective obesity management.
Today

Medical experts caution that GLP-1 receptor agonists offer metabolic support rather than a curative answer for polyendocrine metabolic ovarian syndrome. Clinicians must evaluate glycemic markers, reproductive plans, and lifestyle interventions while discouraging unsupervised medication use among female patients.
Today

Recent research highlights how endoplasmic reticulum and mitochondrial interactions at contact sites regulate ferroptosis in cardiovascular diseases. This article explores lipid peroxidation, organelle crosstalk, and potential therapeutic strategies for ischemic heart disease and heart failure.
Today

A systematic review demonstrates that teriparatide significantly improves healing in medication-related osteonecrosis of the jaw (MRONJ), especially when combined with surgical and non-surgical therapies. This review explores clinical evidence, biological mechanisms, and treatment protocols for clinicians.
Today

An updated meta-analysis shows that 37% of patients remain euthyroid after stopping thyroid hormone therapy, with success rising to 41% in subclinical hypothyroidism. Clinicians can safely consider supervised deprescribing in selected individuals using structured monitoring.
Today